FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1618498759> ?p ?o ?g. }

• W1618498759 endingPage "2346" @default.
• W1618498759 startingPage "2338" @default.
• W1618498759 abstract "We examined the combination of the mammalian target of rapamycin inhibitor everolimus with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM) in a phase I/II study. All patients received six cycles of the combination of everolimus/rituximab or everolimus/bortezomib/rituximab followed by maintenance with everolimus until progression. Forty-six patients were treated; 98% received prior rituximab and 57% received prior bortezomib. No dose-limiting toxicities were observed in the phase I. The most common treatment-related toxicities of all grades were fatigue (63%), anemia (54%), leucopenia (52%), neutropenia (48%) and diarrhea (43%). Thirty-six (78%) of the 46 patients received full dose therapy (FDT) of the three drugs. Of these 36, 2 (6%) had complete response (90% confidence interval (CI): 1–16). In all, 32/36 (89%) of patients experienced at least a minimal response (90% CI: 76–96%). The observed partial response or better response rate was 19/36 (53, 90 CI: 38–67%). For the 36 FDT patients, the median progression-free survival was 21 months (95% CI: 12–not estimable). In summary, this study demonstrates that the combination of everolimus, bortezomib and rituximab is well tolerated and achieved 89% response rate even in patients previously treated, making it a possible model of non-chemotherapeutic-based combination therapy in WM." @default.
• W1618498759 created "2016-06-24" @default.
• W1618498759 creator A5000527476 @default.
• W1618498759 creator A5007419382 @default.
• W1618498759 creator A5009466687 @default.
• W1618498759 creator A5013262501 @default.
• W1618498759 creator A5015287155 @default.
• W1618498759 creator A5023152679 @default.
• W1618498759 creator A5024726033 @default.
• W1618498759 creator A5025000402 @default.
• W1618498759 creator A5033781840 @default.
• W1618498759 creator A5043526996 @default.
• W1618498759 creator A5049433553 @default.
• W1618498759 creator A5049900530 @default.
• W1618498759 creator A5053410437 @default.
• W1618498759 creator A5054625098 @default.
• W1618498759 creator A5072050682 @default.
• W1618498759 creator A5075607061 @default.
• W1618498759 creator A5076820900 @default.
• W1618498759 creator A5081041356 @default.
• W1618498759 creator A5081299017 @default.
• W1618498759 creator A5084109094 @default.
• W1618498759 date "2015-07-03" @default.
• W1618498759 modified "2023-10-14" @default.
• W1618498759 title "Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia" @default.
• W1618498759 cites W1916527093 @default.
• W1618498759 cites W1966407423 @default.
• W1618498759 cites W1967904168 @default.
• W1618498759 cites W1991386861 @default.
• W1618498759 cites W1995125949 @default.
• W1618498759 cites W1995735611 @default.
• W1618498759 cites W2012671933 @default.
• W1618498759 cites W2013453542 @default.
• W1618498759 cites W2015601011 @default.
• W1618498759 cites W2015975538 @default.
• W1618498759 cites W2016652432 @default.
• W1618498759 cites W2017720810 @default.
• W1618498759 cites W2037983836 @default.
• W1618498759 cites W2039945582 @default.
• W1618498759 cites W2042887247 @default.
• W1618498759 cites W2050974188 @default.
• W1618498759 cites W2052855201 @default.
• W1618498759 cites W2055127103 @default.
• W1618498759 cites W2071549499 @default.
• W1618498759 cites W2082084740 @default.
• W1618498759 cites W2098608922 @default.
• W1618498759 cites W2098912234 @default.
• W1618498759 cites W2109562682 @default.
• W1618498759 cites W2116572046 @default.
• W1618498759 cites W2117582823 @default.
• W1618498759 cites W2118677643 @default.
• W1618498759 cites W2128139299 @default.
• W1618498759 cites W2128490833 @default.
• W1618498759 cites W2135050229 @default.
• W1618498759 cites W2138189974 @default.
• W1618498759 cites W2140380015 @default.
• W1618498759 cites W2155518647 @default.
• W1618498759 cites W2160940401 @default.
• W1618498759 cites W2163579973 @default.
• W1618498759 cites W2298933471 @default.
• W1618498759 cites W3190289852 @default.
• W1618498759 cites W3214976431 @default.
• W1618498759 cites W4234743110 @default.
• W1618498759 doi "https://doi.org/10.1038/leu.2015.164" @default.
• W1618498759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26139427" @default.
• W1618498759 hasPublicationYear "2015" @default.
• W1618498759 type Work @default.
• W1618498759 sameAs 1618498759 @default.
• W1618498759 citedByCount "30" @default.
• W1618498759 countsByYear W16184987592016 @default.
• W1618498759 countsByYear W16184987592017 @default.
• W1618498759 countsByYear W16184987592018 @default.
• W1618498759 countsByYear W16184987592019 @default.
• W1618498759 countsByYear W16184987592020 @default.
• W1618498759 countsByYear W16184987592021 @default.
• W1618498759 countsByYear W16184987592022 @default.
• W1618498759 countsByYear W16184987592023 @default.
• W1618498759 crossrefType "journal-article" @default.
• W1618498759 hasAuthorship W1618498759A5000527476 @default.
• W1618498759 hasAuthorship W1618498759A5007419382 @default.
• W1618498759 hasAuthorship W1618498759A5009466687 @default.
• W1618498759 hasAuthorship W1618498759A5013262501 @default.
• W1618498759 hasAuthorship W1618498759A5015287155 @default.
• W1618498759 hasAuthorship W1618498759A5023152679 @default.
• W1618498759 hasAuthorship W1618498759A5024726033 @default.
• W1618498759 hasAuthorship W1618498759A5025000402 @default.
• W1618498759 hasAuthorship W1618498759A5033781840 @default.
• W1618498759 hasAuthorship W1618498759A5043526996 @default.
• W1618498759 hasAuthorship W1618498759A5049433553 @default.
• W1618498759 hasAuthorship W1618498759A5049900530 @default.
• W1618498759 hasAuthorship W1618498759A5053410437 @default.
• W1618498759 hasAuthorship W1618498759A5054625098 @default.
• W1618498759 hasAuthorship W1618498759A5072050682 @default.
• W1618498759 hasAuthorship W1618498759A5075607061 @default.
• W1618498759 hasAuthorship W1618498759A5076820900 @default.
• W1618498759 hasAuthorship W1618498759A5081041356 @default.
• W1618498759 hasAuthorship W1618498759A5081299017 @default.
• W1618498759 hasAuthorship W1618498759A5084109094 @default.

• next